Related references
Note: Only part of the references are listed.Ursodeoxycholic Acid Amides As Novel Glucocorticoid Receptor Modulators
Ruchika Sharma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The role of secondary bile acids in neoplastic development in the oesophagus
James Cronin et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2010)
Bile acids modulate the Golgi membrane fission process via a protein kinase Cη and protein kinase D-dependent pathway in colonic epithelial cells
Anne-Marie Byrne et al.
CARCINOGENESIS (2010)
Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study
Armand Garioud et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells
Nikos J. Tsagarakis et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Cachexia as a major underestimated and unmet medical need: facts and numbers
Stephan von Haehling et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2010)
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
Stephan von Haehling et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2010)
Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR
Rebecca Feldman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Cachexia: A new definition
William J. Evans et al.
CLINICAL NUTRITION (2008)
Catabolic mediators of cancer cachexia
Michael J Tisdale
Current Opinion in Supportive and Palliative Care (2008)
Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice
Hiroyuki Kohno et al.
CLINICAL CANCER RESEARCH (2007)
The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention
Xinhai Zhang et al.
CURRENT CANCER DRUG TARGETS (2007)
Ursodeoxycholic acid inhibits interleukin beta 1 and deoxycholic acid-induced activation of NF-κB and AP-1 in human colon cancer cells
SA Shah et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by 6-CSF and antibiotic prophylaxis
A Bauhofer et al.
LANGENBECKS ARCHIVES OF SURGERY (2001)
Management of primary biliary cirrhosis
EJ Heathcote
HEPATOLOGY (2000)